These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 31344778)

  • 1. Urinary Metabolomics Validates Metabolic Differentiation Between Renal Cell Carcinoma Stages and Reveals a Unique Metabolic Profile for Oncocytomas.
    Falegan OS; Arnold Egloff SA; Zijlstra A; Hyndman ME; Vogel HJ
    Metabolites; 2019 Jul; 9(8):. PubMed ID: 31344778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urine and Serum Metabolomics Analyses May Distinguish between Stages of Renal Cell Carcinoma.
    Falegan OS; Ball MW; Shaykhutdinov RA; Pieroraio PM; Farshidfar F; Vogel HJ; Allaf ME; Hyndman ME
    Metabolites; 2017 Feb; 7(1):. PubMed ID: 28165361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are growth patterns on MRI in small (< 4 cm) solid renal masses useful for predicting benign histology?
    Lim RS; McInnes MDF; Siddaiah M; Flood TA; Lavallee LT; Schieda N
    Eur Radiol; 2018 Aug; 28(8):3115-3124. PubMed ID: 29492598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C-kit expression in renal oncocytomas and chromophobe renal cell carcinomas.
    Huo L; Sugimura J; Tretiakova MS; Patton KT; Gupta R; Popov B; Laskin WB; Yeldandi A; Teh BT; Yang XJ
    Hum Pathol; 2005 Mar; 36(3):262-8. PubMed ID: 15791570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of Relative Enhancement on Multiphasic MRI for the Differentiation of Clear Cell Renal Cell Carcinoma (RCC) From Papillary and Chromophobe RCC Subtypes and Oncocytoma.
    Young JR; Coy H; Kim HJ; Douek M; Lo P; Pantuck AJ; Raman SS
    AJR Am J Roentgenol; 2017 Apr; 208(4):812-819. PubMed ID: 28125273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KIT and RCC are useful in distinguishing chromophobe renal cell carcinoma from the granular variant of clear cell renal cell carcinoma.
    Wang HY; Mills SE
    Am J Surg Pathol; 2005 May; 29(5):640-6. PubMed ID: 15832088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clear cell renal cell carcinoma: discrimination from other renal cell carcinoma subtypes and oncocytoma at multiphasic multidetector CT.
    Young JR; Margolis D; Sauk S; Pantuck AJ; Sayre J; Raman SS
    Radiology; 2013 May; 267(2):444-53. PubMed ID: 23382290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Messenger RNA expression ratios among four genes predict subtypes of renal cell carcinoma and distinguish oncocytoma from carcinoma.
    Chen YT; Tu JJ; Kao J; Zhou XK; Mazumdar M
    Clin Cancer Res; 2005 Sep; 11(18):6558-66. PubMed ID: 16166433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the metabolomic profile of renal cell carcinoma by high resolution magic angle spinning proton magnetic resonance spectroscopy.
    Huynh MJ; Gusev A; Palmas F; Vandergrift L; Berker Y; Wu CL; Wu S; Cheng LL; Feldman AS
    Urol Oncol; 2023 Nov; 41(11):459.e9-459.e16. PubMed ID: 37863744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subtype Differentiation of Small (≤ 4 cm) Solid Renal Mass Using Volumetric Histogram Analysis of DWI at 3-T MRI.
    Li A; Xing W; Li H; Hu Y; Hu D; Li Z; Kamel IR
    AJR Am J Roentgenol; 2018 Sep; 211(3):614-623. PubMed ID: 29812980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nuclear Magnetic Resonance metabolomics reveals an excretory metabolic signature of renal cell carcinoma.
    Monteiro MS; Barros AS; Pinto J; Carvalho M; Pires-Luís AS; Henrique R; Jerónimo C; Bastos ML; Gil AM; Guedes de Pinho P
    Sci Rep; 2016 Nov; 6():37275. PubMed ID: 27857216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a DNA Methylation-Based Diagnostic Signature to Distinguish Benign Oncocytoma From Renal Cell Carcinoma.
    Brennan K; Metzner TJ; Kao CS; Massie CE; Stewart GD; Haile RW; Brooks JD; Hitchins MP; Leppert JT; Gevaert O
    JCO Precis Oncol; 2020; 4():. PubMed ID: 33015531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discrimination of oncocytoma and chromophobe renal cell carcinoma using MRI.
    Akın IB; Altay C; Güler E; Çamlıdağ İ; Harman M; Danacı M; Tuna B; Yörükoğlu K; Seçil M
    Diagn Interv Radiol; 2019 Jan; 25(1):5-13. PubMed ID: 30644365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A miRNA-based classification of renal cell carcinoma subtypes by PCR and
    Di Meo A; Saleeb R; Wala SJ; Khella HW; Ding Q; Zhai H; Krishan K; Krizova A; Gabril M; Evans A; Brimo F; Pasic MD; Finelli A; Diamandis EP; Yousef GM
    Oncotarget; 2018 Jan; 9(2):2092-2104. PubMed ID: 29416756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urine aquaporin 1 and perilipin 2 differentiate renal carcinomas from other imaged renal masses and bladder and prostate cancer.
    Morrissey JJ; Mobley J; Figenshau RS; Vetter J; Bhayani S; Kharasch ED
    Mayo Clin Proc; 2015 Jan; 90(1):35-42. PubMed ID: 25572193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The value of blood oxygenation level-dependent (BOLD) MR imaging in differentiation of renal solid mass and grading of renal cell carcinoma (RCC): analysis based on the largest cross-sectional area versus the entire whole tumour.
    Wu GY; Suo ST; Lu Q; Zhang J; Zhu WQ; Xu JR
    PLoS One; 2015; 10(4):e0123431. PubMed ID: 25875306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differentiation of oncocytoma from chromophobe renal cell carcinoma (RCC): can novel molecular biomarkers help solve an old problem?
    Ng KL; Rajandram R; Morais C; Yap NY; Samaratunga H; Gobe GC; Wood ST
    J Clin Pathol; 2014 Feb; 67(2):97-104. PubMed ID: 24170213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot investigation of a urinary metabolic biomarker discovery in renal cell carcinoma.
    Zhang M; Liu X; Liu X; Li H; Sun W; Zhang Y
    Int Urol Nephrol; 2020 Mar; 52(3):437-446. PubMed ID: 31732842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CCND1 rearrangements and cyclin D1 overexpression in renal oncocytomas: frequency, clinicopathologic features, and utility in differentiation from chromophobe renal cell carcinoma.
    Sukov WR; Ketterling RP; Lager DJ; Carlson AW; Sinnwell JP; Chow GK; Jenkins RB; Cheville JC
    Hum Pathol; 2009 Sep; 40(9):1296-303. PubMed ID: 19386349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of renal oncocytoma with focus on clinical and pathobiological aspects.
    Kuroda N; Toi M; Hiroi M; Shuin T; Enzan H
    Histol Histopathol; 2003 Jul; 18(3):935-42. PubMed ID: 12792905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.